Browsing by Subject "drugs"
Now showing 1 - 9 of 9
- Results Per Page
- Sort Options
Item Antifungal Susceptibilities Among Different Serotypes Of Cryptococcus Gattii And Cryptococcus Neoformans(2009-01) Thompson, George R.; Wiederhold, Nathan P.; Fothergill, Annette W.; Vallor, Ana C.; Wickes, Brian L.; Patterson, Thomas F.; Wiederhold, Nathan P.We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.Item Drug Policy Framing(2023-02-21) Lozano, BrennaItem Effects of pharmaceutical wastes on growth of microalgae(1970) Van Baalen, C. (Chase), 1925-1986; Batterton, JohnThe purpose of this work was to assay samples of waste material from Puerto Rican pharmaceutical industries for inhibition of growth of algae. Two samples (noted as I and II) supplied to us were tested for toxicity to six microalgae. The test organisms, two blue-green algae, two green algae, and two diatoms [r]epresent three major divisions of algae.Item Experimental Drug Access for Terminally-Ill Patients: A Review of the Right to Try Act(2021-12) Dighe, AshkaEarly access to drugs that have not won approval from the United States Food and Drug Administration (FDA) is a heavily debated topic across academics and subject matter experts in the United States, especially regarding use for terminally-ill patients. The debates surrounding whether it should be legal, what restrictions should be put in place, and what freedoms or rights individuals are entitled to continue to raise ethical questions and concerns about policy implementation. The Right to Try Act, signed into law in 2018, is a policy that effectively removes the necessity of FDA approval, granting terminally-ill patients access to non-FDA-approved drugs. This thesis explores the historical examples that underpin the Right to Try Act, the ethical considerations associated with its promulgation, and policy recommendations to improve the current system for accessing experimental drugs. For numerous reasons addressed throughout this paper, granting physicians and pharmaceutical companies sole control of non-FDA approved drugs yields too much risk to the patient and opens these entities to greater liability. The Right to Try Act causes safety concerns and removes supervision over access to under-researched therapeutics. The best system—one that prioritizes patients and their autonomy, manages safety risks of non-FDA approved drugs, and mitigates the potential for unethical practices—requires federal oversight. To build this type of system, the FDA should retain the authority to protect medical ethics and the integrity of the medical establishment.Item Final report : NOAA Puerto Rico pharmaceutical wastes, January 11, 1980(1980) Van Baalen, C. (Chase), 1925-1986Individual pharmaceutical wastes from operations in Puerto Rico were examined for toxicity towards representative types of microalgae.Item Further Experiments on the Use of Drugs as Stimulants in Accidents Occuring During Anaesthesia(University of Texas at Austin, 1911-02-08) University of Texas at AustinItem New Era Requires New Approach to Drug Approvals(2020-06-19) Brooks, SteveItem Presentation: Exploring Myths About Addiction(Environmental Science Institute, 2001-11-16) Erickson, Carlton; Environmental Science InstituteItem The Relationship between Illegal Drugs and Violence: Is There a Cause and Effect?(Teresa Lozano Long Institute of Latin American Studies, 2010) Thoumi, Francisco E.